首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Ertapenem-associated seizures in a patient without prior CNS disorder or severe renal dysfunction.
【24h】

Ertapenem-associated seizures in a patient without prior CNS disorder or severe renal dysfunction.

机译:没有先前中枢神经系统疾病或严重肾功能不全的患者中厄他培南相关的癫痫发作。

获取原文
获取原文并翻译 | 示例
           

摘要

To present a case report of a patient who had developed seizures during ertapenem therapy with no central nervous system (CNS) disorder and the dose of ertapenem that is apparently appropriate according to the renal function.Seizures are rare but well known side-effects of carbapenems, especially imipenem. In most cases, seizures develop in patients with CNS lesions and limited carbapenem excretion. We present a case of a female patient with no prior central nervous disorder who developed seizures after 3 days of ertapenem therapy. In the first 2 days, the dose of ertapenem was halved according to the calculated creatinine clearance. On day 3, the renal function improved, and according to the recommendation by the manufacturer there was no need for dose adjustment any more. Seizures stopped after the discontinuation of ertapenem and anti-epileptic prophylaxis with levetiracetam. A literature search of similar case reports has shown that seizures during ertapenem treatment may develop in patients with prior known CNS disorders and/or severe renal dysfunction that predicts dose alteration according to renal function. There are reports of changed mental status with no convulsive movements, and there is known decrease of valproic acid concentration during ertapenem treatment in patients treated for various forms of epilepsy. To our knowledge, this is the first report of ertapenem-related seizures in a patient with normal CNS function and the dose of ertapenem that was appropriate for her renal function.With our case report, we would like to inform and warn clinicians of the possibility of new onset epilepsy during ertapenem treatment, even in individuals with pre-existing moderate chronic kidney disease and no prior known CNS disease.
机译:提交一例患者报告,该患者在厄他培南治疗期间发作而无中枢神经系统(CNS)障碍,并且依他肾功能显然合适的厄他培南剂量很常见,但癫痫发作的副作用很广,但众所周知,尤其是亚胺培南。在大多数情况下,中枢神经系统病变和碳青霉烯排泄受限的患者会出现癫痫发作。我们介绍了一名女性患者,该患者先前没有中枢神经疾病,但在厄他培南治疗3天后出现癫痫发作。在头2天,根据计算出的肌酐清除率将厄他培南的剂量减半。在第3天,肾功能改善,并且根据制造商的建议,不再需要调整剂量。停用厄他培南并用左乙拉西坦预防癫痫发作后,癫痫发作停止。对类似病例报告的文献搜索显示,在厄他培南治疗期间癫痫发作可能会发生在先前已知的中枢神经系统疾病和/或严重肾功能不全的患者中,这些患者会根据肾功能预测剂量变化。有报告说,精神状态发生了变化,没有抽搐运动,已知在厄他培南治疗期间接受各种形式癫痫治疗的患者中丙戊酸浓度降低。据我们所知,这是中枢神经系统功能正常患者中厄他培南相关癫痫发作的首次报道,以及适合其肾功能的厄他培南剂量。我们希望通过病例报告告知临床医生这种可能性在厄他培南治疗期间发生了新的癫痫病,即使是在已患有中度慢性肾脏疾病且没有先前已知的中枢神经系统疾病的个体中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号